- Home
- Industry Reports
- Healthcare
- Pharmaceuticals
- Asia Pacific Nuclear Medicine Radioisotopes Market – Growth & Forecast (2024 – 2032)
Nuclear medicine uses radiation to provide information about the functioning of a person’s specific organs or to treat disease. In most cases, the information is used by physicians to make a quick diagnosis of the patient’s illness. The thyroid, bones, heart, liver, and many other organs can be easily imaged, and disorders in their function revealed.
Asia-Pacific Nuclear Medicine Radioisotopes Market Segments Size & Growth:
Asia-Pacific nuclear medicine radioisotopes market is projected to reach approximately $XX billion by the end of 2024 with aCAGR of close to 11.55% from $XX billion in 2017 during the forecast timeline 2018-2024. Key parameters promoting the market growth include growing patient awareness, increasing SPECT and PET applications, development of better instruments and rising incidences of cancer and cardiac disorders. However, Reimbursement Problems and Strict Regulatory Issues are thereby hampering the market growth.
Asia-Pacific Nuclear Medicine Radioisotopes Market Segments Share:
Asia-Pacific nuclear medicine radioisotopes market is categorised into a type of radioisotopes which comprise of Iridium, Palladium, Iodine, Technetium, Cesium, and Others.Among them, Technetium holds the most significant share in the market. By Applications, the market is segmented into Neurology, Thyroid, Lymphoma, and Others.On the basis of Geography, India and China are projected to dominate the market with the most significant share and the growth in the Asia-Pacific economies is mainly attributed because of huge profit margins and growth prospects.
Asia-Pacific Nuclear Medicine Radioisotopes Market Trends:
- Nuclear medicine has grown because of advances in technology, including hybrid imaging, the introduction of new radiopharmaceuticals for diagnosis and therapy, and the development of molecular imaging based on the tracer principle, which is not based on radioisotopes. Uniform growth of the field will require cost-effectiveness data and evidence that nuclear medicine procedures affect patients’ outcomes. Nuclear medicine physicians and radiologists will need more training in anatomic and molecular imaging. New educational models are being developed to ensure that future physicians will be adequately prepared.
- GE Healthcare has entered into a strategic, long-term partnership with Roche to develop and co-market digital clinical decision support solutions jointly. The partnership will initially focus on products that accelerate and improve individualised treatment options for cancer and critical care patients. The two companies are aiming to develop an industry-first digital platform, using advanced analytics to provide workflow solutions and apps that support clinical decisions. This will allow the seamless integration and analysis of in-vivo and in-vitro data, patient records, medical best practice, real-time monitoring and the latest research outcomes.
Asia-Pacific Nuclear Medicine Radioisotopes Market Research Report:
An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
To have complete market analysis, industry value chain analysis, Porter’s Five Force Analysis, PESTLE, SWOT analysis, and Y-o-Y analysis were carried to understand the market more comprehensively.
Regional diversity is analysed with the major countries and the unions. Scrutinizing the revenue generation on Year-On-Year
Identifying DROC in the current market and their impact in altering the market dynamics.
Competitive landscape analysis to identify the mergers and acquisitions which will have a comparative financial study with significant competitors.
Expertise investment opportunities by an analyst to the individual and organisation to have a better foothold in the market.
The primary market players, such as
- Bracco Imaging S.P.A.
- Cambridge Isotope Laboratories
- Cardinal Health, Inc.
- Covidien, Plc.
- Eczacibasi-Monrol
1.Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
3. Market Analysis
3.1 Industry Value Chain Analysis
3.2 Porter’s Five Analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 Pestle Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4 SWOT Analysis
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threats
3.5 Y-O-Y Analyses
4. Market Dynamics
4.1 Drivers
4.1.1Growing Patient awareness
4.1.2Increasing SPECT and PET applications
4.1.3 Development of better instruments
4.14 Rising incidences of Cancer and Cardiac disorders
4.2 Restraints
4.2.1Reimbursement Problems
4.2.2Strict Regulatory Issues
4.3 Opportunities
4.3.1 Cyclotron based production
4.3.2 Increasing neurological applications
4.3.3 Potential Radioisotopes in the pipeline
4.4.4 Increasing Imaging Technologies
4.4 Challenges
4.4.1 Shutdown of Nuclear Reactors to Impact Production of Radioisotopes
5. Asia-Pacific Nuclear Medicine Radioisotopes Market –By Type of Radioisotopes
5.1Iridium-192
5.2 Palladium-103
5.3 Iodine-125
5.4 Cesium-131
5.5 Thorium-227 (Th-227)
5.6 Radium-224 (Ra-224)
5.7 Astatine-211 (At-211)
5.8 Lead-212 (Pb-212)/Bismuth-212 (Bi-212)
5.9 Actinium-225 (Ac-225)
5.10 Radium-223 (Ra-223) & Alpharadin
5.11 Lutetium-177 (Lu-177)
5.12 Rhenium-186 (Re-186)
5.13 Samarium-153 (Sm-153)
5.14 Yttrium-90 (Y-90)
5.15 Iodine-131 (I-131)
5.16 Rubidium-82 (Rb-82)
5.17 Fluorine-18
5.18 Iodine (I-123)
5.19 Thallium-201 (Tl-201)
5.20 Technetium-99m (Tc-99m)
5.21 Others
6. Asia-Pacific Nuclear Medicine Radioisotopes Market-By Applications
6.1 Neurology
6.2 Thyroid
6.3 Lymphoma
6.4 Cardiology
6.5 Oncology
6.6 Others
7. Asia-Pacific Nuclear Medicine Radioisotopes Market – By Country
7.1. Introduction
7.2. India
7.3. China
7.4. Japan
7.5 Rest of Asia-Pacific
8. Company Profiles
8.1 Medix Inc.
8.2 IBA Molecular Imaging
8.3 Lantheus Medical Imaging Inc.
8.4 Bayer Healthcare
8.5 Naviscan Inc.
8.6 Bracco Imaging S.P.A
8.7 Positron Corporation
8.8 Segami Corporation
8.9 Hologic Inc.
8.10 GE Healthcare
8.11 Cardinal Health, Inc.
8.12 Mallinckrodt PLC
8.13 Eczacibasi-Monrol Nuclear Products
8.14 Nordion, Inc.
8.15 Advanced Accelerator Applications S.A.
9. Asia-Pacific Nuclear Medicine Radioisotopes Market –Competitive Landscape
9.1 Market Share Analysis
9.2 Strategies Adopted by top companies
9.3 Mergers, Acquisitions, Collaborations & Agreements
10. Market Insights
10.1 Insights of Industry Experts
10.2 Investment Opportunities
10.3 Analyst Opinion
11. Appendix
11.1 List of Tables
11.2 List of Figures
- Competitive Analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors.
- Monitoring the external and internal factors which affect the market dynamics with the aid of PESTLE analysis.
- The Regional and Global Variety is taken care of in the report.
- Year on Year basis generation of revenue is studied.
- Porter's Five Forces analyze the intensity of competition in an industry and its profitability level.
- The overview and the sustainability of the market are analyzed through SWOT.
- DROC (Drivers, Restraints, Opportunities and Challenges) is recognized in the current market scenario and see how its effect on market dynamics.
- The segment-level analysis in terms of type and technology.
- The value chain analysis, value that's created and captured by a company is the profit margin.
- Value Created and Captured – Cost of Creating that Value = Margin
- An executive summary consists of the whole report and the outcome is been given in the report to have brief knowledge about the report.
- Basis on the depth of the study we approach using analytical tools
- Expertise investment opportunities are given after analyzing the market to give the organization and the individual to have perfect knowledge about the market.
Regional Report
$2,160.00 – $7,200.00
- EUR: €1,991.88 - €6,639.62
- INR: ₹180,043.09 - ₹600,143.64
- AED: د.إ7,927.20 - د.إ26,424.00
- GBP: £1,706.75 - £5,689.16
Description
Regional Reports
Additional information
Report Type | Extensive Report, Miniature report, Snapshot Report |
---|---|
Licence | Single User License, Team License, Corporate License |
Nuclear medicine uses radiation to provide information about the functioning of a person’s specific organs or to treat disease. In most cases, the information is used by physicians to make a quick diagnosis of the patient’s illness. The thyroid, bones, heart, liver, and many other organs can be easily imaged, and disorders in their function revealed.
Asia-Pacific Nuclear Medicine Radioisotopes Market Segments Size & Growth:
Asia-Pacific nuclear medicine radioisotopes market is projected to reach approximately $XX billion by the end of 2024 with aCAGR of close to 11.55% from $XX billion in 2017 during the forecast timeline 2018-2024. Key parameters promoting the market growth include growing patient awareness, increasing SPECT and PET applications, development of better instruments and rising incidences of cancer and cardiac disorders. However, Reimbursement Problems and Strict Regulatory Issues are thereby hampering the market growth.
Asia-Pacific Nuclear Medicine Radioisotopes Market Segments Share:
Asia-Pacific nuclear medicine radioisotopes market is categorised into a type of radioisotopes which comprise of Iridium, Palladium, Iodine, Technetium, Cesium, and Others.Among them, Technetium holds the most significant share in the market. By Applications, the market is segmented into Neurology, Thyroid, Lymphoma, and Others.On the basis of Geography, India and China are projected to dominate the market with the most significant share and the growth in the Asia-Pacific economies is mainly attributed because of huge profit margins and growth prospects.
Asia-Pacific Nuclear Medicine Radioisotopes Market Trends:
- Nuclear medicine has grown because of advances in technology, including hybrid imaging, the introduction of new radiopharmaceuticals for diagnosis and therapy, and the development of molecular imaging based on the tracer principle, which is not based on radioisotopes. Uniform growth of the field will require cost-effectiveness data and evidence that nuclear medicine procedures affect patients’ outcomes. Nuclear medicine physicians and radiologists will need more training in anatomic and molecular imaging. New educational models are being developed to ensure that future physicians will be adequately prepared.
- GE Healthcare has entered into a strategic, long-term partnership with Roche to develop and co-market digital clinical decision support solutions jointly. The partnership will initially focus on products that accelerate and improve individualised treatment options for cancer and critical care patients. The two companies are aiming to develop an industry-first digital platform, using advanced analytics to provide workflow solutions and apps that support clinical decisions. This will allow the seamless integration and analysis of in-vivo and in-vitro data, patient records, medical best practice, real-time monitoring and the latest research outcomes.
Asia-Pacific Nuclear Medicine Radioisotopes Market Research Report:
An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
To have complete market analysis, industry value chain analysis, Porter’s Five Force Analysis, PESTLE, SWOT analysis, and Y-o-Y analysis were carried to understand the market more comprehensively.
Regional diversity is analysed with the major countries and the unions. Scrutinizing the revenue generation on Year-On-Year
Identifying DROC in the current market and their impact in altering the market dynamics.
Competitive landscape analysis to identify the mergers and acquisitions which will have a comparative financial study with significant competitors.
Expertise investment opportunities by an analyst to the individual and organisation to have a better foothold in the market.
The primary market players, such as
- Bracco Imaging S.P.A.
- Cambridge Isotope Laboratories
- Cardinal Health, Inc.
- Covidien, Plc.
- Eczacibasi-Monrol
1.Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
3. Market Analysis
3.1 Industry Value Chain Analysis
3.2 Porter’s Five Analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 Pestle Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4 SWOT Analysis
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threats
3.5 Y-O-Y Analyses
4. Market Dynamics
4.1 Drivers
4.1.1Growing Patient awareness
4.1.2Increasing SPECT and PET applications
4.1.3 Development of better instruments
4.14 Rising incidences of Cancer and Cardiac disorders
4.2 Restraints
4.2.1Reimbursement Problems
4.2.2Strict Regulatory Issues
4.3 Opportunities
4.3.1 Cyclotron based production
4.3.2 Increasing neurological applications
4.3.3 Potential Radioisotopes in the pipeline
4.4.4 Increasing Imaging Technologies
4.4 Challenges
4.4.1 Shutdown of Nuclear Reactors to Impact Production of Radioisotopes
5. Asia-Pacific Nuclear Medicine Radioisotopes Market –By Type of Radioisotopes
5.1Iridium-192
5.2 Palladium-103
5.3 Iodine-125
5.4 Cesium-131
5.5 Thorium-227 (Th-227)
5.6 Radium-224 (Ra-224)
5.7 Astatine-211 (At-211)
5.8 Lead-212 (Pb-212)/Bismuth-212 (Bi-212)
5.9 Actinium-225 (Ac-225)
5.10 Radium-223 (Ra-223) & Alpharadin
5.11 Lutetium-177 (Lu-177)
5.12 Rhenium-186 (Re-186)
5.13 Samarium-153 (Sm-153)
5.14 Yttrium-90 (Y-90)
5.15 Iodine-131 (I-131)
5.16 Rubidium-82 (Rb-82)
5.17 Fluorine-18
5.18 Iodine (I-123)
5.19 Thallium-201 (Tl-201)
5.20 Technetium-99m (Tc-99m)
5.21 Others
6. Asia-Pacific Nuclear Medicine Radioisotopes Market-By Applications
6.1 Neurology
6.2 Thyroid
6.3 Lymphoma
6.4 Cardiology
6.5 Oncology
6.6 Others
7. Asia-Pacific Nuclear Medicine Radioisotopes Market – By Country
7.1. Introduction
7.2. India
7.3. China
7.4. Japan
7.5 Rest of Asia-Pacific
8. Company Profiles
8.1 Medix Inc.
8.2 IBA Molecular Imaging
8.3 Lantheus Medical Imaging Inc.
8.4 Bayer Healthcare
8.5 Naviscan Inc.
8.6 Bracco Imaging S.P.A
8.7 Positron Corporation
8.8 Segami Corporation
8.9 Hologic Inc.
8.10 GE Healthcare
8.11 Cardinal Health, Inc.
8.12 Mallinckrodt PLC
8.13 Eczacibasi-Monrol Nuclear Products
8.14 Nordion, Inc.
8.15 Advanced Accelerator Applications S.A.
9. Asia-Pacific Nuclear Medicine Radioisotopes Market –Competitive Landscape
9.1 Market Share Analysis
9.2 Strategies Adopted by top companies
9.3 Mergers, Acquisitions, Collaborations & Agreements
10. Market Insights
10.1 Insights of Industry Experts
10.2 Investment Opportunities
10.3 Analyst Opinion
11. Appendix
11.1 List of Tables
11.2 List of Figures
- Competitive Analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors.
- Monitoring the external and internal factors which affect the market dynamics with the aid of PESTLE analysis.
- The Regional and Global Variety is taken care of in the report.
- Year on Year basis generation of revenue is studied.
- Porter's Five Forces analyze the intensity of competition in an industry and its profitability level.
- The overview and the sustainability of the market are analyzed through SWOT.
- DROC (Drivers, Restraints, Opportunities and Challenges) is recognized in the current market scenario and see how its effect on market dynamics.
- The segment-level analysis in terms of type and technology.
- The value chain analysis, value that's created and captured by a company is the profit margin.
- Value Created and Captured – Cost of Creating that Value = Margin
- An executive summary consists of the whole report and the outcome is been given in the report to have brief knowledge about the report.
- Basis on the depth of the study we approach using analytical tools
- Expertise investment opportunities are given after analyzing the market to give the organization and the individual to have perfect knowledge about the market.
Our Clientele
Exclusive Benefits
Credibility and Transparency
We actively recruit consumers, business professionals, and hard-to-reach individuals as members of our research panels, and we build trusted, ongoing relationships with them. Thus we provide the complete list of primary and secondary data sources in the report to maintain the transparency and to assure the credibility.
Exhaustive Coverage
Detailed and extensive coverage in the geography.Survey consultation for brand tracking, concept testing, consumer behaviour, and more, we have you covered with market research services that scale to meet your needs.
Competitive Edge
Our reports cover most recent updates in the market till the date of the purchase. We identify, gather and timely deliver analysis on impact of unprecedented decisions of CXOs in COVID-19 catastrophe on many businesses, their clients and their clients' clients without additional cost.
Golden Opportunities
A comprehensive strategic sieve analysis of the market by our analysts and consultants, aided by AI tools helps us find the non-obvious, golden and emerging opportunities for you to evaluate.
Top-notch Reports Guaranteed
70% of our research is exclusive; no other research firm has the depth and breadth of our research.
Post Purchase Support
Post-purchase support is provided for all our reports, for three months from the date of purchase, where related queries will be answered within 24 business hours over telephone or email.